Marker Therapeutics, Inc. (MRKR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 2.5M 5M 7.5M FY17: 183.1K FY18: 206K FY19: 213.2K FY20: 500K FY21: 0 FY22: 3.5M FY23: 3.3M FY24: 6.6M FY25: 3.5M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-180M -120M -60M 0 60M 120M 180M FY10: -5.5M FY11: -3.3M FY13: -2.7M FY14: -3.4M FY15: -6.2M FY16: -8.5M FY17: -11.5M FY18: -148.2M FY19: -22.5M FY20: -28.9M FY21: -39.5M FY22: -19.8M FY23: -14.6M FY24: -11.1M FY25: -12.9M FY10 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-180M -120M -60M 0 60M 120M 180M FY00: -935.3K FY01: -672K FY02: -2.3M FY03: -5.8M FY04: -2.7M FY05: -985.6K FY06: -1.3M FY07: -3.9M FY08: -2.2M FY09: -17.3M FY10: -3.5M FY11: -2M FY12: -5.9M FY13: -5.5M FY14: -30.9M FY15: -34.1M FY16: -2.5M FY17: -11M FY18: -148M FY19: -21.4M FY20: -28.7M FY21: -41.9M FY22: -29.9M FY23: -8.2M FY24: -10.7M FY25: -12.2M FY01 FY04 FY07 FY10 FY13 FY16 FY19 FY22 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-30M -20M -10M 0 10M 20M 30M FY10: -925K FY11: -1.3M FY12: -1.6M FY13: -694.6K FY13: -694.6K FY14: -2.2M FY15: -4.3M FY16: -6.5M FY17: -8.4M FY18: -14.5M FY19: -18.3M FY20: -20M FY21: -27.3M FY22: -27M FY23: -16.4M FY24: -10.9M FY25: -12M FY10 FY12 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-21M -14M -7M 0 7M 14M 21M FY17: -8.4M FY18: -14.6M FY19: -18.7M FY17 FY18 FY19

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 20M 40M 60M FY15: 3.7M FY16: 7.4M FY17: 9.5M FY18: 19.1M FY19: 45.6M FY20: 47M FY21: 7.7M FY22: 8.4M FY23: 8.8M FY24: 9M FY25: 15.3M FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q4 '11: -0.04 Q1 '12: -0.02 Q2 '12: -0.05 Q3 '12: -0.04 Q4 '12: -0.08 Q1 '13: -0.62 Q4 '13: -4.87 Q1 '14: -8.39 Q2 '14: -7.47 Q3 '14: -6.80 Q4 '16: -0.93 Q1 '17: -0.41 Q2 '17: -0.98 Q3 '17: -1.08 Q4 '17: -1.15 Q1 '18: -1.16 Q2 '18: -1.35 Q3 '18: -1.28 Q4 '18: -7.75 Q1 '19: -7.57 Q2 '19: -7.28 Q3 '19: -7.08 Q4 '19: -0.47 Q1 '20: -0.49 Q2 '20: -0.51 Q3 '20: -0.55 Q4 '20: -0.62 Q1 '21: -0.64 Q2 '21: -0.63 Q3 '21: -0.62 Q4 '21: -5.48 Q1 '22: -6.51 Q2 '22: -7.49 Q3 '22: -8.17 Q4 '22: -3.58 Q1 '23: -2.96 Q2 '23: -1.56 Q3 '23: -1.07 Q4 '23: -0.94 Q1 '24: -0.64 Q2 '24: -1.18 Q3 '24: -1.10 Q4 '24: -1.20 Q1 '25: -1.33 Q2 '25: -1.37 Q3 '25: -1.23 Q4 '25: -0.85 Q1 '26: -0.61 Q2 '26: -0.41 Q4 '13 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.